Key result
Treatment with a γδ TCR monoclonal antibody in mice on a high-fat diet reduced inflammation, improved gut microbiota, and decreased atherosclerotic lesion burden.
Why the study?
Does γδ T cell receptor monoclonal antibody reduce atherosclerosis progression in mice on a high-fat diet?
Does γδ T cell receptor monoclonal antibody reduce atherosclerosis progression in mice on a high-fat diet?
Inhibition of γδ T cells attenuates atherosclerosis progression and reduces inflammation in a high-fat diet mouse model, suggesting a potential therapeutic target.
Background: mice. Methods: mice were assigned to three groups: a control group (normal diet), a model group (HFD), and an intervention group (HFD + γδ T cell receptor (TCR) monoclonal antibody). After 12 weeks, flow cytometry was used to assess γδ T cell levels, and cytokines (interferon-gamma (IFN-γ), IL-17A) were measured. Inflammatory markers in blood and adipose tissue were quantified, gut microbiota composition was analyzed via fecal metagenomics, and atherosclerosis was evaluated using Oil Red O, Masson's trichrome, and hematoxylin and eosin (HE) staining methods. Results: mice. Treatment with the γδ TCR monoclonal antibody suppressed γδ T cells, reduced IFN-γ and IL-17A expression, improved lipid profiles, and decreased tumor necrosis factor-alpha (TNF-α), IL-1β, and IL-6 levels. Gut microbiota analysis showed an increase in beneficial bacteria, and histological staining (Oil Red O, HE, and Masson's trichrome) confirmed a reduction in atherosclerotic lesion burden. Conclusion: The γδ T cells contribute to AS development under the HFD. Inhibition of γδ T cells reduces inflammation, improves gut microbiota composition, and attenuates atherosclerosis progression.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Atherosclerosis. γδ T cell receptor (TCR) monoclonal antibody vs. High-fat diet (model group) and normal diet (control group) was evaluated on Atherosclerosis progression, inflammatory markers, and gut microbiota composition. Treatment with a γδ TCR monoclonal antibody in mice on a high-fat diet reduced inflammation, improved gut microbiota, and decreased atherosclerotic lesion burden.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: